IRIS
SILVESTRIS, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.827
EU - Europa 2.326
AS - Asia 1.487
SA - Sud America 372
AF - Africa 19
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.035
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.775
SE - Svezia 726
SG - Singapore 671
RU - Federazione Russa 573
CN - Cina 508
BR - Brasile 350
GB - Regno Unito 185
FR - Francia 164
IT - Italia 164
DE - Germania 129
BE - Belgio 110
IN - India 69
HK - Hong Kong 62
FI - Finlandia 53
UA - Ucraina 43
ID - Indonesia 38
VN - Vietnam 38
CZ - Repubblica Ceca 37
CA - Canada 34
AT - Austria 23
TR - Turchia 17
IR - Iran 14
IE - Irlanda 13
NL - Olanda 12
BG - Bulgaria 11
AR - Argentina 9
ES - Italia 9
JP - Giappone 8
PL - Polonia 8
BD - Bangladesh 7
HR - Croazia 7
RS - Serbia 7
UZ - Uzbekistan 7
IL - Israele 6
IQ - Iraq 6
LT - Lituania 6
MX - Messico 6
RO - Romania 6
NO - Norvegia 5
PT - Portogallo 5
AL - Albania 4
DK - Danimarca 4
HU - Ungheria 4
KZ - Kazakistan 4
MA - Marocco 4
PK - Pakistan 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
AU - Australia 3
CH - Svizzera 3
CO - Colombia 3
EG - Egitto 3
MT - Malta 3
NG - Nigeria 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
HN - Honduras 2
KW - Kuwait 2
LV - Lettonia 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
A1 - Anonimo 1
BS - Bahamas 1
BT - Bhutan 1
CL - Cile 1
EC - Ecuador 1
GL - Groenlandia 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MC - Monaco 1
ME - Montenegro 1
NP - Nepal 1
PY - Paraguay 1
SA - Arabia Saudita 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 17.035
Salva come PNG Salva come JPEG
Città #
Fairfield 2.057
Chandler 1.769
Ashburn 1.171
Woodbridge 1.034
Cambridge 908
Seattle 908
Houston 817
Wilmington 649
Nyköping 569
Ann Arbor 397
Singapore 396
Lawrence 245
Roxbury 230
Des Moines 146
Beijing 141
Brussels 108
Paris 104
San Diego 97
Inglewood 92
Dearborn 88
New York 86
Jacksonville 78
Council Bluffs 75
Moscow 70
Brooklyn 62
Los Angeles 59
London 56
Hong Kong 55
Pune 54
Bari 52
Boardman 50
Santa Clara 46
Nanjing 40
Jakarta 38
Washington 34
Helsinki 33
Brno 26
Edinburgh 26
San Mateo 26
Falls Church 23
Princeton 23
Dong Ket 22
The Dalles 21
Ruvo Di Puglia 20
Jinan 19
Munich 19
Frankfurt am Main 18
Monmouth Junction 17
Norwalk 17
Düsseldorf 16
Hefei 16
Rio de Janeiro 16
Shanghai 16
Vienna 16
Guangzhou 15
Augusta 14
Dublin 13
Grafing 13
Jiaxing 13
Marseille 13
Belo Horizonte 12
Falkenstein 12
Hanoi 11
Leawood 11
Nuremberg 11
Prescot 11
São Paulo 11
Toronto 11
Zhengzhou 11
Chicago 10
Nanchang 10
Ottawa 10
Rome 10
Shenyang 10
Sofia 10
Ardabil 9
Kilburn 9
Brasília 8
Kunming 8
Olomouc 8
Amsterdam 7
Dallas 7
Hebei 7
Madrid 7
Porto Alegre 7
Stockholm 7
Tashkent 7
Tokyo 7
Warsaw 7
Zagreb 7
Atlanta 6
Belgrade 6
Campinas 6
Changsha 6
Chiswick 6
Hounslow 6
Lauterbourg 6
Miami 6
Milan 6
Montreal 6
Totale 13.585
Salva come PNG Salva come JPEG
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 196
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 147
Angiogenesis in adenosquamous cancer of pancreas 137
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 135
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 127
Targeting angiogenesis in biliary tract cancers: An open option 126
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 122
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 121
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 121
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 117
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 114
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 109
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 108
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 107
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 105
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 105
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 104
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 104
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 104
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 102
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 101
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 101
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 101
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 100
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 100
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 99
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 99
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 99
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 98
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 98
Challenges and opportunities of MicroRNAs in lymphomas 97
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 96
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 96
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 96
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 96
Bone metastases in biliary cancers: A multicenter retrospective survey 96
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 95
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 95
Immunotherapeutic approaches for hepatocellular carcinoma 93
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 93
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 92
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 91
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 91
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 91
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 89
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 88
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 88
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 88
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 88
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 88
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 88
Antineoplastic drug-induced bradyarrhythmias 88
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 88
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 88
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 87
Synthetic lethality to overcome cancer drug resistance 87
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 87
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 87
Adjuvant therapy in colon cancer 87
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 86
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 86
p53 as the main traffic controller of the cell signaling network 86
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 85
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 85
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 83
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 83
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 83
Target therapies in pancreatic carcinoma 83
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 83
Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma 82
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 82
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 82
Combined modality treatments in pancreatic cancer 82
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 82
Oncosuppressor methylation: A possible key role in colon metastatic progression 82
null 81
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 81
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 81
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 81
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 81
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 80
Current status of targeted therapies in advanced gastric cancer 80
Molecular classifications of gastric cancers: Novel insights and possible future applications 80
null 80
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 80
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 80
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 80
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 80
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report 79
Management of patients with end-stage renal disease undergoing chemotherapy: Recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN) 79
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 79
New molecular targets in bone metastases 78
Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department 78
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 77
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 77
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 77
[Apoptosis or programmed cell death: regulatory and pathophysiological mechanisms]. FT Apoptosi, o morte cellulare programmata: meccanismi regolatori e fisiopatologia. 76
Immunotherapy for colorectal cancer: where are we heading? 76
The Italian Rare Pancreatic Exocrine Cancer Initiative 76
Synchronous Mandibular and Giant Parieto-occipital Skull Metastasis From Hepatocellular Carcinoma 76
Totale 9.349
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020463 0 0 0 0 0 0 0 0 0 0 333 130
2020/20213.157 229 178 417 369 287 330 206 254 217 285 266 119
2021/20222.210 158 210 40 77 159 151 111 133 142 113 227 689
2022/20233.704 403 517 292 362 319 414 111 475 541 26 204 40
2023/20241.173 84 216 80 103 124 324 19 66 9 28 10 110
2024/20252.655 96 83 364 208 154 517 390 427 163 224 29 0
Totale 17.638